DCP
LXEO icon

D1 Capital Partners’s Lexeo Therapeutics LXEO Stock Holding History

D1 Capital Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-978,652
Closed -$6.5M – 46
2025
Q3 		$6.5M Hold
978,652
– – 0.07% 38
2025
Q2 		$3.93M Hold
978,652
– – 0.05% 33
2025
Q1 		$3.4M Sell
978,652
-1,225,248
-56% -$5.43M 0.05% 41
2024
Q4 		$14.5M Sell
2,203,900
-302,707
-12% -$2.38M 0.24% 35
2024
Q3 		$22.7M Hold
2,506,607
– – 0.44% 31
2024
Q2 		$40.2M Hold
2,506,607
– – 0.68% 29
2024
Q1 		$39.3M Hold
2,506,607
– – 0.6% 32
2023
Q4 		$33.6M Buy
+2,506,607
New +$31.1M 0.59% 28

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

D1 Capital Partners's LXEO Position: Q4 2025 in Review

D1 Capital Partners sold out of Lexeo Therapeutics (LXEO) in Q4 2025, closing a stake of 978,652 shares — an estimated $6.5M sold.

D1 Capital Partners first reported a position in LXEO in Q4 2023 and held it in 8 quarters. The position peaked at $40.2M in Q2 2024. 146 funds tracked by Wall St. Rank hold LXEO as of Q4 2025.

  • D1 Capital Partners reported no remaining Lexeo Therapeutics position as of Q4 2025 after selling out during the quarter.
  • D1 Capital Partners sold 978,652 Lexeo Therapeutics shares in Q4 2025, an estimated $6.5M.
  • D1 Capital Partners first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 8 quarters.
  • D1 Capital Partners's Lexeo Therapeutics position peaked at $40.2M in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q4 2025.

Based on D1 Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.